Q32 Bio Inc. (NASDAQ:QTTB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Q32 Bio Inc. (NASDAQ:QTTB) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $13.50.

QTTB has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Cantor Fitzgerald initiated coverage on shares of Q32 Bio in a report on Monday, May 18th. They issued an “overweight” rating for the company. Zacks Research lowered shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Mizuho initiated coverage on shares of Q32 Bio in a report on Friday, May 22nd. They issued an “outperform” rating and a $14.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Q32 Bio in a report on Tuesday, May 5th.

Insider Buying and Selling

In other Q32 Bio news, Director Diyong Xu acquired 1,875,000 shares of the stock in a transaction dated Thursday, May 28th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the acquisition, the director owned 3,502,987 shares in the company, valued at $28,023,896. The trade was a 115.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc acquired 1,875,000 shares of the stock in a transaction dated Thursday, May 28th. The stock was acquired at an average price of $8.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the director owned 3,502,987 shares in the company, valued at approximately $28,023,896. The trade was a 115.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 34.46% of the company’s stock.

Institutional Investors Weigh In On Q32 Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in Q32 Bio during the 2nd quarter valued at $25,000. Acadian Asset Management LLC bought a new stake in Q32 Bio during the 1st quarter valued at $50,000. Two Sigma Investments LP bought a new stake in Q32 Bio during the 3rd quarter valued at $62,000. ADAR1 Capital Management LLC bought a new stake in Q32 Bio during the 4th quarter valued at $66,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio during the 1st quarter valued at $68,000. 31.32% of the stock is currently owned by institutional investors.

Q32 Bio Price Performance

QTTB stock opened at $11.90 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.36 and a quick ratio of 5.36. Q32 Bio has a one year low of $1.35 and a one year high of $14.85. The stock has a market cap of $201.82 million, a PE ratio of 4.47 and a beta of 0.27. The firm has a 50 day simple moving average of $8.17 and a two-hundred day simple moving average of $5.73.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.14. On average, analysts predict that Q32 Bio will post -1.96 EPS for the current fiscal year.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.